439112-49-9

Upstream product

• 439112-48-8 4-methoxyphenylacetic acid (E)-4-(benzyloxy)but-2-enyl ester 
• 457653-91-7 (2S,3R)-3-(benzyloxymethyl)-2-(4-methoxyphenyl)pent-4-enoic acid L-(-)-α-methylbenzylammonium salt 
• 100-39-0 benzyl bromide 
• 4039-82-1 Benzyl propargyl ether 
• 91142-50-6 4-benzyloxy-2-butyn-1-ol 
• 80885-30-9 (E)-4-(benzyloxy)-2-buten-1-ol 

Downstream Products

• 439112-50-2 (2S,3R)-3-(benzyloxymethyl)-2-(4-methoxyphenyl)pent-4-enoic acid (S)-2,2-dimethyl-1-(methylcarbamoyl)propylamide 
• 205807-59-6 TNF₄₈₄ 

Relevant academic research and scientific papers

HYDROXAMIC ACID DERIVATIVES

Novel hydroxamic acid derivatives, e.g., of formula (I), wherein R1, R2, R3 and R4 are as defined, are found to be useful as pharmaceuticals, e.g., for the suppression of TNF release and the treatment of autoimm

Process development of a dual MMP/TNF inhibitor (SDZ 242-484)

The compound (2R,3S)-N-4-((S)-2,2-Dimethyl-1-methylcarbamoyl-propyl)-N-1-hydroxy-2- hydroxymethyl-3-(4-methoxy-phenyl)-succinamide (1; SDZ 242-484) shows antiinflammatory effects due to inhibition of matrix metalloproteases (MMP) and tumor necrosis factor

β-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme

Novel hydroxamate inhibitors of tumor necrosis factor converting enzyme (TACE) and matrix metalloproteases (MMPs) have been synthesized via the Claisen-Ireland rearrangement. Aryl residues have been introduced to fill the enzyme's P1′ specificity pocket. The best compound inhibits MMPs and TACE with nanomolar potency and inhibits the release of TNFα from cells with an IC50 of 48 nM. Oral administration to rats inhibits the LPS-induced plasma TNFα levels with an ED50 of 1 mg/kg.